31 articles about Femasys
Femasys Inc. today announced the appointment of James Liu, M.D., as Chief Medical Officer.
Femasys Inc. today announced completion of enrollment in the LOCAL FemaSeed® pivotal clinical trial, designed to evaluate women undergoing FemaSeed cycles due to male factor infertility.
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide.
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
Femasys Inc. today announced a strategic upfront investment of $6.85 million by public biotech company, PharmaCyte Biotech, Inc. (Nasdaq: PMCB) and other healthcare investors.
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
Femasys Inc. today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
Femasys Inc. today announced that it will highlight its product candidate in late stage clinical development, FemBloc ® , as well as showcase three of its marketed products advancing women’s health FemVue®, FemCath® and FemCerv®, at the annual meeting of the American Association of Gynecologic Laparoscopic Surgeons (AAGL) being held in Nashville, Tennessee from November 5-8, 2023.
Femasys Inc. announced that it has it has received notice from The Nasdaq Stock Market LLC informing Femasys that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
Femasys Inc. today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): “The Past, The Present, and The Pipeline”, being held in New Orleans.
Femasys Inc. today announced that it has successfully completed the annual Medical Device Single Audit Program (MDSAP) surveillance audit with no nonconformances and no findings.
Femasys Inc. today announced that it has activated enrollment for its pivotal FemBloc trial at its first academic site located in Brooklyn, New York.
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
Femasys Inc. (NASDAQ: FEMY) today announced it has received 510(k) Clearance from the United States Food and Drug Administration (FDA) for FemaSeed®, an innovative infertility treatment designed to deliver sperm directly to where conception occurs in a woman’s fallopian tube.
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
Femasys Inc. today announced the achievement of First-Patient-In for its pivotal clinical trial evaluating FemBloc ® , a first-of-its-kind, non-surgical, non-implant, in-office solution for permanent birth control for women.
Femasys Inc. today announced that Kathy Lee-Sepsick, founder, president & chief executive officer, will virtually present and also participate in one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.
Femasys Inc. announced that it has obtained a Medical Device Establishment License from Health Canada.
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
Femasys Inc. announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc- First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial -
Femasys Inc. announced the initiation of enrollment in a prospective multi-center pivotal trial for FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Control (the “FINALE” trial), to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc®.
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control
Femasys Inc. announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 16/402,193 further strengthening Femasys’ intellectual property position and coverage for the Company’s therapeutic product candidate, FemBloc® permanent birth control.
Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
Femasys Inc. announced today the approval of an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA) to evaluate the safety and efficacy of FemBloc®, a first-of-its-kind, non-surgical, non-implant, in-office solution for permanent birth control in a pivotal clinical trial (the “FINALE” trial).
Femasys Inc. announced that it has appointed Mr. Keith J. Kendall and Mr. Alistair Milnes to its board of directors.
Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
Femasys Inc. announced that Kathy Lee-Sepsick, founder, president & chief executive officer, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.